DOSAGE INDEX / SINGLE
ARA-290
Research, reported schedules and supply planning.
Review ARA-290 and cibinetide human neuropathy studies, corneal nerve measurements, pain outcomes and safety findings with evidence limits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
Reported example 1
- Amount
- 4 mg per administration
- Frequency
- Once daily
- Cycle / observation period
- 28 days
- Route / research model
- Subcutaneous
This page describes a study regimen. The 16 mg vial page instead adds a starting phase and a longer course; the two schedules differ.
Reported example 2
- Amount
- 2 mg in the first week, then 4 mg per day
- Frequency
- Once daily
- Cycle / observation period
- 8 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
This source schedule extends beyond the 28-day trial summary available in our evidence entry. Its added starting phase and duration are not verified here.
Titration & progression
The selected example uses a fixed amount; no stepwise titration is specified for this planning window.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–28 | 4 mg | Daily |
Compare the product label or clinical-study schedule
64 adults with sarcoidosis-associated small-nerve-fiber loss and neuropathic pain in the 2017 phase 2b trial.
Cibinetide (ARA-290) was studied at 1, 4 or 8 mg daily by subcutaneous administration for 28 days, compared with placebo. These were parallel dose groups. They were not instructions to progress from one amount to the next.
The 4 mg group improved the primary corneal nerve-area endpoint. The reported moderate-to-severe pain subgroup comparison had P=.157. A structural endpoint does not establish a generally effective neuropathy treatment or a preferred self-selected dose.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
28-day study schedule; distinct from the longer source example: 112 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 10 mg | 12 |
| 16 mg | 7 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2011 study tested ARA-290 after experimental peripheral nerve injury in rats and mice. It reduced tactile and cold allodynia in ordinary animals but not in mice lacking the beta-common receptor. The finding supported a role for that receptor in the observed response. [3]
- A blinded, placebo-controlled sarcoidosis study evaluated 28 days of subcutaneous ARA-290. It reported improvement in neuropathic symptoms and increased corneal small-nerve-fiber density, together with changes in sensory and functional assessments. [6]
- A 2017 randomized, 28-day trial enrolled 64 patients with sarcoidosis-associated small-nerve-fiber loss and pain. Its primary endpoint was corneal nerve fiber area. The middle dose group improved significantly versus placebo; the lower and higher groups did not. In the moderate-to-severe pain subgroup, the middle-dose placebo-adjusted pain comparison had P=.157. [2]
- The phase 2b report lists injection-site pain, diarrhea, fatigue, headache and nausea among frequent adverse events. It also reports serious events judged unrelated in two participants and suicidal ideation in one participant judged possibly related to study treatment. [7]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 55 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original peptide-development study
- Original cibinetide trial
- Original receptor-knockout experiment
- Original spinal-response study
- Original randomized pilot
- Original follow-up clinical study
- Original full trial report, safety section
- Original diabetes and neuropathy study
- Original rat and islet experiments
- IUPHAR/BPS Guide to Pharmacology: Cibinetide (ARA-290) ligand profile, structure, and pharmacologyFurther reading · Listed in reference bibliography.
- Hand and Brines, Journal of Investigative Medicine (2011): Promises and pitfalls in erythropoietin-mediated tissue protectionFurther reading · Listed in reference bibliography.
- ClinicalTrials.gov NCT02039687: Sarcoidosis dose-ranging study with 1 mg, 4 mg, and 8 mg subcutaneous arms for 28 daysTrial registry · Listed in reference bibliography.
- van Velzen et al., Expert Opinion on Investigational Drugs (2014): Review of ARA-290 research in sarcoidosis-related small-fiber neuropathyFurther reading · Listed in reference bibliography.
- Davis et al., Pain Reports (2017): Review of innate repair receptor targeting for neuropathyFurther reading · Listed in reference bibliography.
- Zhang et al., Peptides (2016): Preclinical study of ARA-290 and TRPV1-related pain signalingFurther reading · Listed in reference bibliography.
- European Respiratory Society Clinical Practice Guideline (2021): Insufficient evidence to support a recommendation for sarcoidosis-related small-fiber neuropathyFurther reading · Listed in reference bibliography.
- ClinicalTrials.gov NCT01933529: Study record for 4 mg ARA-290 daily for 28 days in impaired glucose tolerance or type 2 diabetesTrial registry · Listed in reference bibliography.
- Annersten and Willman, Worldviews on Evidence-Based Nursing (2005): Literature review of the evidence base for subcutaneous injection techniqueFurther reading · Listed in reference bibliography.
- McLennan et al., Drug Discovery Today: Technologies (2005): Review of subcutaneous drug delivery and lymphatic absorptionFurther reading · Listed in reference bibliography.
- Usach et al., Advanced Drug Delivery Reviews (2019): Pharmacologic considerations for subcutaneous drug deliveryFurther reading · Listed in reference bibliography.
- Bittner et al., BioDrugs (2018): Review of the challenges and opportunities in subcutaneous administration of biotherapeuticsFurther reading · Listed in reference bibliography.
- Collino et al., Pharmacology & Therapeutics (2015): Review of ARA-290 pharmacology and innate repair receptor signalingFurther reading · Listed in reference bibliography.
- Journal of Internal Medicine (2008)Further reading · Listed in reference bibliography.
- Molecular Medicine (2014)Further reading · Listed in reference bibliography.
- Molecular Medicine (2013)Further reading · Listed in reference bibliography.
- EU Clinical Trials Register, EudraCT 2013-003016-45 Posted results for 1 mg, 4 mg, and 8 mg ARA-290 subcutaneous arms administered for 28 consecutive days.Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- USP General ChaptersFurther reading · Listed in reference bibliography.
- Cleveland ClinicFurther reading · Listed in reference bibliography.
- Pain Reports (2017)Further reading · Listed in reference bibliography.
- Investigative Ophthalmology & Visual Science (2016)Further reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.